{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:35:07Z","timestamp":1789763707278,"version":"4.0.1"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroinflammation, a complex process involving the activation of microglia, astrocytes, and other immune cells in the brain, plays a role in neurodegeneration and psychiatric disorders. Current therapeutic strategies for neuroinflammation are limited, necessitating the development of improved approaches. Nanopharmacology offers unprecedented opportunities to access and treat neuroinflammatory disorders at the brain level. Nanoscaffolds can target specific cells or tissues and protect drugs from degradation or elimination, making them ideal candidates for treating neurodegenerative and psychiatric diseases. Recent advancements in nanoparticle development have enabled the targeting of microglia, astrocytes, and other immune cells in the brain, reducing neuroinflammation and protecting neurons from injury. Nanoparticles targeting specific neurons have also been developed. Clinical trials are in progress to evaluate the safety and efficacy of nano drugs for treating neuroinflammatory, neurodegenerative, and psychiatric diseases. The successful development of these nanodrugs holds immense promise for treating these devastating and increasingly prevalent conditions. On the other hand, several limitations and unanswered questions remain. First, the long-term effects of nanoparticles on the brain need to be thoroughly investigated to ensure their safety. Second, optimizing the targeting and delivery of nanoparticles to specific brain regions remains a challenge. Understanding the complex interplay between nanoparticles and the brain\u2019s immune system is crucial for developing effective nanotherapies. Despite these limitations, nanopharmacology presents a transformative approach to treating neuroinflammatory disorders. Future research should address the aforementioned limitations and further elucidate the mechanisms of nanoparticle-mediated therapy. The successful development of safe and effective nanodrugs can revolutionize the treatment of neuroinflammatory disorders, alleviating the suffering of millions.<\/jats:p>","DOI":"10.1515\/tnsci-2022-0328","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T23:58:33Z","timestamp":1702684713000},"source":"Crossref","is-referenced-by-count":16,"title":["Nanopharmacology as a new approach to treat neuroinflammatory disorders"],"prefix":"10.1515","volume":"14","author":[{"given":"Sebasti\u00e1n Garc\u00eda","family":"Men\u00e9ndez","sequence":"first","affiliation":[{"name":"Instituto de Medicina y Biolog\u00eda Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Cient\u00edficas y Tecnol\u00f3gicas (CONICET) , Mendoza , Argentina"},{"name":"\u00c1rea de Farmacolog\u00eda. Departamento de Patolog\u00eda , Facultad de Ciencias M\u00e9dicas , Universidad Nacional de Cuyo , Mendoza , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Manucha","sequence":"additional","affiliation":[{"name":"Instituto de Medicina y Biolog\u00eda Experimental de Cuyo (IMBECU), Consejo Nacional de Investigaciones Cient\u00edficas y Tecnol\u00f3gicas (CONICET) , Mendoza , Argentina"},{"name":"\u00c1rea de Farmacolog\u00eda. Departamento de Patolog\u00eda , Facultad de Ciencias M\u00e9dicas , Universidad Nacional de Cuyo , Mendoza , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,12,16]]},"reference":[{"key":"2023121604582605896_j_tnsci-2022-0328_ref_001","doi-asserted-by":"crossref","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022;23(3):1851. 10.3390\/ijms23031851.","DOI":"10.3390\/ijms23031851"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_002","doi-asserted-by":"crossref","unstructured":"Mittal KR, Pharasi N, Sarna B, Singh M, Rachana, Haider S, et al. Nanotechnology-based drug delivery for the treatment of CNS disorders. Transl Neurosci. 2022;13(1):527\u201346. 10.1515\/tnsci-2022-0258.","DOI":"10.1515\/tnsci-2022-0258"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_003","doi-asserted-by":"crossref","unstructured":"Waris A, Asmat Ali A, Khan AU, Asim M, Zamel D, Fatima K, et al. Applications of various types of nanomaterials for the treatment of neurological disorders. Nanomaterials (Basel). 2022;12(13):2140. 10.3390\/nano12132140.","DOI":"10.3390\/nano12132140"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_004","doi-asserted-by":"crossref","unstructured":"Ullah SNMN, Afzal O, Altamimi ASA, Ather H, Sultana S, Almalki WH, et al. Nanomedicine in the management of Alzheimer\u2019s disease: State-of-the-art. Biomedicines. 2023;11(6):1752. 10.3390\/biomedicines11061752.","DOI":"10.3390\/biomedicines11061752"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_005","doi-asserted-by":"crossref","unstructured":"Rathnam SS, Deepak T, Sahoo BN, Meena T, Singh Y, Joshi A. Metallic nanocarriers for therapeutic peptides: Emerging solutions addressing the delivery challenges in brain ailments. J Pharmacol Exp Ther. 2023. 10.1124\/jpet.123.001689.","DOI":"10.1124\/jpet.123.001689"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_006","doi-asserted-by":"crossref","unstructured":"Novellino F, Sacc\u00e0 V, Donato A, Zaffino P, Spadea MF, Vismara M, et al. Innate immunity: A common denominator between neurodegenerative and neuropsychiatric diseases. Int J Mol Sci. 2020;21(3):1115. 10.3390\/ijms21031115.","DOI":"10.3390\/ijms21031115"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_007","doi-asserted-by":"crossref","unstructured":"Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine. 2019;14(1):93\u2013126. 10.2217\/nnm-2018-0120.","DOI":"10.2217\/nnm-2018-0120"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_008","doi-asserted-by":"crossref","unstructured":"Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193. 10.3390\/molecules25092193.","DOI":"10.3390\/molecules25092193"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_009","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez VMM, Men\u00e9ndez SG, Manucha W. Nanomedicine and addictive disorders: A new approach with cannabinoids. Curr Pharm Des. 2022;28(34):2795\u20139. 10.2174\/1381612828666220907104354.","DOI":"10.2174\/1381612828666220907104354"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_010","doi-asserted-by":"crossref","unstructured":"Wang L, Shi Y, Jiang J, Li C, Zhang H, Zhang X, et al. Micro-nanocarriers based drug delivery technology for blood-brain barrier crossing and brain tumor targeting therapy. Small. 2022;18(45):e2203678. 10.1002\/smll.202203678.","DOI":"10.1002\/smll.202203678"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_011","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez VMM, Fuentes LB, Kassuha DE, Manucha W. Current drug nano-targeting strategies for improvement in the diagnosis and treatment of prevalent pathologies such as cardiovascular and renal diseases. Curr Drug Targets. 2019;20(14):1496\u2013504. 10.2174\/1389450120666190702162533.","DOI":"10.2174\/1389450120666190702162533"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_012","unstructured":"Feng L, Huang J, Chen M, Zhang H, Hu Y, Wu H, et al. Nanoparticle-based curcumin delivery for improving therapeutic effect on Alzheimer\u2019s disease. J Pharm Sci. 2020;109(4):1892\u20139."},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_013","doi-asserted-by":"crossref","unstructured":"Bakrim S, Aboulaghras S, El Menyiy N, El Omari N, Assaggaf H, Lee LH, et al. Phytochemical compounds and nanoparticles as phytochemical delivery systems for Alzheimer\u2019s disease management. Molecules. 2022;27(24):9043. 10.3390\/molecules27249043.","DOI":"10.3390\/molecules27249043"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_014","doi-asserted-by":"crossref","unstructured":"Duan L, Li X, Ji R, Hao Z, Kong M, Wen X, et al. Nanoparticle-based drug delivery systems: An inspiring therapeutic strategy for neurodegenerative diseases. Polymers (Basel). 2023;15(9):2196. 10.3390\/polym15092196.","DOI":"10.3390\/polym15092196"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_015","doi-asserted-by":"crossref","unstructured":"Fu XX, Qu H, Wang J, Cai HY, Jiang H, Chen HH, et al. Novel nano-carriers with N-formylmethionyl-leucyl-phenylalanine-modified liposomes improve effects of C16-angiopoietin 1 in acute animal model of multiple sclerosis. Drug Deliv. 2023;30(1):2241664. 10.1080\/10717544.2023.2241664.","DOI":"10.1080\/10717544.2023.2241664"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_016","doi-asserted-by":"crossref","unstructured":"Wang T, Lei H, Li X, Yang N, Ma C, Li G, et al. Magnetic targeting nanocarriers combined with focusing ultrasound for enhanced intracerebral hemorrhage therapy. Small. 2023;19(17):e2206982. 10.1002\/smll.202206982.","DOI":"10.1002\/smll.202206982"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_017","doi-asserted-by":"crossref","unstructured":"Li X, Han Z, Wang T, Ma C, Li H, Lei H, et al. Cerium oxide nanoparticles with antioxidative neurorestoration for ischemic stroke. Biomaterials. 2022;291:121904. 10.1016\/j.biomaterials.2022.121904.","DOI":"10.1016\/j.biomaterials.2022.121904"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_018","doi-asserted-by":"crossref","unstructured":"Abdolahi M, Tafakhori A, Togha M, Okhovat AA, Siassi F, Eshraghian MR, et al. The synergistic effects of \u03c9-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-\u03b1 gene expression and serum level in migraine patients. Immunogenetics. 2017;69(6):371\u20138. 10.1007\/s00251-017-0992-8.","DOI":"10.1007\/s00251-017-0992-8"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_019","doi-asserted-by":"crossref","unstructured":"Abdolahi M, Jafarieh A, Sarraf P, Sedighiyan M, Yousefi A, Tafakhori A, et al. The neuromodulatory effects of \u03c9-3 fatty acids and nano-curcumin on the COX-2\/iNOS network in migraines: A clinical trial study from gene expression to clinical symptoms. Endocr Metab Immune Disord Drug Targets. 2019;19(6):874\u201384. 10.2174\/1871530319666190212170140.","DOI":"10.2174\/1871530319666190212170140"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_020","doi-asserted-by":"crossref","unstructured":"Honarvar NM, Soveid N, Abdolahi M, Djalali M, Hatami M, Karzar NH. Anti-Neuroinflammatory properties of n-3 fatty acids and nano- curcumin on migraine patients from cellular to clinical insight: A randomized, double-blind and placebo-controlled trial. Endocr Metab Immune Disord Drug Targets. 2021;21(2):365\u201373. 10.2174\/1871530320666200729144430.","DOI":"10.2174\/1871530320666200729144430"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_021","doi-asserted-by":"crossref","unstructured":"Khalil I, Yehye WA, Etxeberria AE, Alhadi AA, Dezfooli SM, Julkapli NBM, et al. Nanoantioxidants: Recent trends in antioxidant delivery applications. Antioxidants. 2020;9(1):24. 10.3390\/antiox9010024.","DOI":"10.3390\/antiox9010024"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_022","doi-asserted-by":"crossref","unstructured":"Roy RG, Mandal PK, Maroon JC. Oxidative stress occurs prior to amyloid A\u03b2 plaque formation and tau phosphorylation in Alzheimer\u2019s disease: Role of glutathione and metal ions. ACS Chem Neurosci. 2023. Advance online publication. 10.1021\/acschemneuro.3c00486.","DOI":"10.1021\/acschemneuro.3c00486"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_023","doi-asserted-by":"crossref","unstructured":"Shao S, Guo T, Li F, Zhao Z, Li J, Wang X. Experimental study on the therapeutic effect of BDNF gene-carrying nanoparticles on traumatic brain injury. Appl Nanoscience. 2023;13:3447\u201358. 10.1007\/s13204-022-02405-w.","DOI":"10.1007\/s13204-022-02405-w"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_024","doi-asserted-by":"crossref","unstructured":"Xu F, Wu Y, Yang Q, Cheng Y, Xu J, Zhang Y, et al. Engineered extracellular vesicles with SHP2 high expression promote mitophagy for Alzheimer\u2019s disease treatment. Adv Mater. 2022;34(49):e2207107. 10.1002\/adma.202207107.","DOI":"10.1002\/adma.202207107"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_025","doi-asserted-by":"crossref","unstructured":"Abozaid OAR, Sallam MW, El-Sonbaty S, Aziza S, Emad B, Ahmed ESA. Resveratrol-selenium nanoparticles alleviate neuroinflammation and neurotoxicity in a rat model of Alzheimer\u2019s disease by regulating Sirt1\/miRNA-134\/GSK3\u03b2 expression. Biol Trace Elem Res. 2022;200(12):5104\u201314. 10.1007\/s12011-021-03073-7.","DOI":"10.1007\/s12011-021-03073-7"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_026","doi-asserted-by":"crossref","unstructured":"Singla M, Gupta S, Porwal O, Binjawhar DN, Sayed AA, Mittal P, et al. Theoretical design for covering Engeletin with functionalized nanostructure-lipid carriers as neuroprotective agents against Huntington\u2019s disease via the nasal-brain route. Front Pharmacol. 2023;14:1218625. 10.3389\/fphar.2023.1218625.","DOI":"10.3389\/fphar.2023.1218625"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_027","doi-asserted-by":"crossref","unstructured":"Zhu TT, Wang H, Gu HW, Ju LS, Wu XM, Pan WT, et al. Melanin-like polydopamine nanoparticles mediating anti-inflammatory and rescuing synaptic loss for inflammatory depression therapy. J Nanobiotechnol. 2023;21(1):52. 10.1186\/s12951-023-01807-4.","DOI":"10.1186\/s12951-023-01807-4"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_028","doi-asserted-by":"crossref","unstructured":"Nayak V, Patra S, Rout S, Jena AB, Sharma R, Pattanaik KP, et al. Regulation of neuroinflammation in Alzheimer\u2019s disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties. Phytomedicine. 2024;122:155150. 10.1016\/j.phymed.2023.155150.","DOI":"10.1016\/j.phymed.2023.155150"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_029","doi-asserted-by":"crossref","unstructured":"Li J, Peng H, Zhang W, Li M, Wang N, Peng Ch, et al. Enhanced nose-to-brain delivery of combined small interfering RNAs using lesion-recognizing nanoparticles for the synergistic therapy of Alzheimer\u2019s disease. ACS Appl Mater Interfaces. 2023;15(46):53177\u201388. 10.1021\/acsami.3c08756.","DOI":"10.1021\/acsami.3c08756"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_030","doi-asserted-by":"crossref","unstructured":"Allami P, Heidari A, Rezaei N. The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. Front Mol Biosci. 2023;9:1083645. 10.3389\/fmolb.2022.1083645.","DOI":"10.3389\/fmolb.2022.1083645"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_031","doi-asserted-by":"crossref","unstructured":"Mobed A, Charsouei S, Yazdani Y, Gargari MK, Ahmadalipour A, Sadremousavi SR, et al. Biosensors, recent advances in determination of BDNF and NfL. Cell Mol Neurobiol. 2023;43(8):3801\u201314. 10.1007\/s10571-023-01401-0.","DOI":"10.1007\/s10571-023-01401-0"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_032","doi-asserted-by":"crossref","unstructured":"Xiao W, He K, Yu Ch, Zhou Z, Xia L, Xie S, et al. Space station-like composite nanoparticles for co-delivery of multiple natural compounds from chinese medicine and hydrogen in combating sensorineural hearing loss. Mol Pharm. 2023;20(8):3987\u20134006. 10.1021\/acs.molpharmaceut.3c00177.","DOI":"10.1021\/acs.molpharmaceut.3c00177"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_033","doi-asserted-by":"crossref","unstructured":"Metcalfe SM, Bickerton S, Fahmy T. Neurodegenerative disease: A perspective on cell-based therapy in the new era of cell-free nano-therapy. Curr Pharm Des. 2017;23(5):776\u201383. 10.2174\/1381612822666161206141744.","DOI":"10.2174\/1381612822666161206141744"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_034","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez L, Bevilacqua LE, Naves R. Nanotechnology-based drug delivery strategies to repair the mitochondrial function in neuroinflammatory and neurodegenerative diseases. Pharmaceutics. 2021 Dec;13(12):2055. 10.3390\/pharmaceutics13122055.","DOI":"10.3390\/pharmaceutics13122055"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_035","doi-asserted-by":"crossref","unstructured":"Chehelgerdi M, Chehelgerdi M, Allela OQB, Cosme Pecho RD, Jayasankar N, Rao DP, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22:169. 10.1186\/s12943-023-01865-0.","DOI":"10.1186\/s12943-023-01865-0"},{"key":"2023121604582605896_j_tnsci-2022-0328_ref_036","doi-asserted-by":"crossref","unstructured":"Hu L, Tao Y, Jiang Y, Qin F. Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol. 2023;11:1228679. 10.3389\/fcell.2023.1228679.","DOI":"10.3389\/fcell.2023.1228679"}],"container-title":["Translational Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2022-0328\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2022-0328\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T23:58:48Z","timestamp":1702684728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2022-0328\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,16]]},"published-print":{"date-parts":[[2023,12,16]]}},"alternative-id":["10.1515\/tnsci-2022-0328"],"URL":"https:\/\/doi.org\/10.1515\/tnsci-2022-0328","relation":{},"ISSN":["2081-6936"],"issn-type":[{"value":"2081-6936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]},"article-number":"20220328"}}